Aprepitant

Category: pharmacological

Aliases: Emend

Pharmacological Mechanism

Selective NK1 (substance P) receptor antagonist — antiemetic for delayed chemotherapy-induced nausea. CYP3A4 substrate + moderate inhibitor + CYP2C9 inducer — DDI source during oncology regimens.

Half-Life (t½)

PO: 12h, IV: 12h

Dosing Guidelines

• PO: Typical 125mg (Range: 80 - 165 mg)

Target Organ Systems

• digestive
• immune-hematologic

Interactions

• Midazolam
• Dexamethasone
• Tolbutamide